- Joined
- Sep 7, 2014
- Messages
- 3,220
- Reaction score
- 5,951
Wondering how people are doing volumes in BR pancreas when using conventional chemorads. The recently published Preopanc trial based volumes strictly off of gross disease, albeit using a different dose schema. On the other hand, we've historically treated a large volume with ENI from above the celiac down to L2 and into the porta, including the para-aortic, portal venous, celiac, and SMA in the case of head tumors. Based strictly on tolerability, I suspect more people complete the more conservative plans altogether, or without breaks. On the other hand, I would suspect LC is better if treating a larger area, though I'm not aware of the two approaches being compared. It seems the move in unresectable has been towards treating gross disease plus margin alone (if not always that way given the LAP 07 approach), so in my estimation, it also makes sense to treat BR this way as only about 33% should ever undergo a Whipple. In any case, I suspect most are using larger volumes, and haven't really seen the preopanc approach adopted, though perhaps some are using SBRT to gross disease plus margin in BR.